Hepatitis C Virus Management
|
|
- Joel Shaw
- 6 years ago
- Views:
Transcription
1 Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San Francisco, California Slide 3 of 36 Learning Objectives After attending this presentation, participants will be able to: Describe current treatment of hepatitis C virus (HCV) infection Assess the degree of liver fibrosis Describe benefits to liver post cure and ongoing management Identify who needs long-term monitoring Slide 4 of 36 Liver Fibrosis stage is NOT assessed by Transient elastography Liver biopsy APRI FIB-4 Ultrasound New York, New York: February 24,
2 Patients after 5 years (%) Patients after 5 years (%) Slide 5 of 36 Liver Fibrosis stage is NOT assessed by Transient elastography Liver biopsy APRI FIB-4 Ultrasound HCV Deaths vs. Other Notifiable Infectious Diseases (including HIV, TB & HBV) in US Globally HCV ~ million ~ 3.5 million Ab+ (2.7 HCV RNA, likely underestimate ) HIV 36 million 1.2 million Slide 8 of HIV-HCV 36 > 2 million ~ 25% US Ly CID 2016 Effects of SVR on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta analysis, 129 studies, 34,563 patients Hill AASLD year risk of death (all-cause) by SVR General Cirrhotic Co-infected Gen 18 stud n=29,269 Avg. FU=4.6 years SVR No SVR Cirr 9 stud n=2,734 Avg. FU=6.6 years HIV/HCV: 5 stud n=2,560 Avg. FU=5.1 years General: 21 stud n=12,496 Avg. FU=6.1 years Benefits may be offset by re-infection over 5 years 0.9% in low-risk persons 8.2% in persons who inject drugs 23.6% in persons coinfected with HIV 5-year risk of hepatocellular carcinoma by SVR 9.3 SVR 5.3 No SVR General Cirrhotic Co-infected Cirrhotic: 18 stud n=4,987 Avg. FU=6.6 years HIV/HCV: 3 studies n=2,085 Avg. FU=4.7 years Slide 9 of 37 New York, New York: February 24,
3 HCV Therapy is Associated with Better Renal, Cardiovascular Outcomes in Diabetic Patients End-stage renal disease (3 cohorts) Cumulative Incidence (% over time) No Rx Ischaemic stroke (3 cohorts) Rx HCV No HCV HCV Rx HR (95% CI) 0.16 for ESRD, 0.53 for ischemic stroke, and 0.64 for ACS Slide 10 of 36 Hsu YC, et al. Hepatology 2014 Steps in Assessing Fibrosis 1. Noninvasive markers E.g. APRI: Fib 4: use AST, platelets: ALT, age 2. Non invasive assessment of fibrosis Transient elastography ARFI MR fibrosis assessment 3. If further delineation is needed Liver biopsy Not needed in many/ most situations with HCV Slide 11 of 36 Whom to treat: everyone Slide 12 of HCV Overview Treatment is recommended for all patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy. Patients with short life expectancies owing to liver disease should be managed in consultation with an expert. (AASLD/IDSA guidelines) First pangenotype, single pill therapy approved Duration for most patients: 8-12 weeks >95% cure in vast majority of patients Most do not require ribavirin Effective options for historically hardest to treat populations New York, New York: February 24,
4 Approved DAAs From Multiple Classes: Basis of 2016 Combination HCV Regimens Structural Domain Nonstructural Domain 5 UTR Core E1 E2 P7 NS2 NS3 4A NS4B NS5A NS5B 3 UTR Protease Polymerase Ribavirin (RBV) Slide 13 of 36 NS3 Protease Inhibitors Grazoprevir (GZR) Paritaprevir/Ritonavir (PTV/RTV) Simeprevir (SMV) NS5A Replication Complex Inhibitors Daclatasvir (DCV) Elbasvir (EBR) Ledipasvir (LDV) Ombitasvir (OBV) Velpatasvir (VEL) NS5B NUC Inhibitors Sofosbuvir (SOF) Slide credit: clinicaloptions NS5B Non-NUC Inhibitors (NNI) Dasabuvir (DSV) Slide 14 of 36 Current All-Oral Regimens for HCV Infection Regimen Component Classes Approved Genotypes Grazoprevir/elbasvir Ombitasvir/paritaprevir/ritonavir Ombitasvir/paritaprevir/ritonavir + dasabuvir Sofosbuvir + daclatasvir Sofosbuvir/ledipasvir Protease inhibitor + NS5A inhibitor Protease inhibitor + NS5A inhibitor Protease inhibitor + NS5A inhibitor + polymerase inhibitor Nucleotide polymerase inhibitor + NS5A inhibitor Nucleotide polymerase inhibitor + NS5A inhibitor Simeprevir + sofosbuvir Nucleotide polymerase inhibitor + protease inhibitor 1 Sofosbuvir/velpatasvir References in HCV guidelines on line Nucleotide polymerase inhibitor + NS5A inhibitor Slide credit: clinicaloptions 1, , 3 1, 4, 5, 6 1, 2, 3, 4, 5, 6 Slide 15 of 36 Major New Developments in 2016 Elbasvir/grazoprevir FDA approved for GT1a/b and 4 With renal disease (crcl <30) Lower SVR12 rates in pts with BL NS5A RAVs associated with > 5-fold loss of EBR susceptibility (2/9, 22%) Sofosbuvir/velpatasvir FDA approved for GT1-6: 97% SVR Use for genotype 2 Ombitasvir/paritaprevir/ritonavir/dasabuvir RBV RBV not needed for GT1b (TURQUOISE-III) Ombitasvir/paritaprevir/ritonavir/dasabuvir once daily coformulation FDA approved for GT1 Feld NEJM 2015; Foster NEJM 2015 New York, New York: February 24,
5 Slide 16 of 36 PPI and DAA LDV and VEL less soluble in high ph with PPIs LDV use lower doses of PPI: comparable to 20 mg omeprazole under fasted conditions VEL- don t use PPI If needed give SOF VEL with food 4 hrs before omeprazole 20 mg Data on other PPIs unknown Treatment naive PEG RBV Recommended Regimens for HCV Genotype 1a Slide AASLD/IDSA. 17 of 36 HCV guidance.october Recommended no Cirrhotic 12 wks EBV/GRZ (no RAVs) 12 wks LDVSOF 12 wks PRoD 12 wks SIM + SOF 16 wks EBV/GRZ (NS5A RAVs) 12 wks EBV/GRZ (if no RAVs) 12 wks PRoD + RBV 12 wks SIM + SOF 16 wks EBV/GRZ (NS5A RAVs) Recommended Compensated Cirrhotic 12 wks EBV/GRZ (no RAVs) 12 wks EBV/GRZ (no RAVs) 16 wks EBV/GRZ (NS5A RAVs) Slide 18 of 36 Recommended Regimens for HCV Genotype 1b Tx Experienced Recommended non cirrhotic Recommended Compensated Cirrhotic naive PEG RBV 12 wks EBV/GRZ 12 wks PRoD 12 wks SIM + SOF 12 wks EBV/GRZ 12 wks PRoD + RBV 12 wks SIM + SOF AASLD/IDSA. HCV guidance. September wks EBV/GRZ 12 wks PRoD 12 wks EBV/GRZ 12 wks PRoD New York, New York: February 24,
6 Recommended Regimens for HCV Genotype 1 failures Tx Experienced Recommended non cirrhotic Recommended Cirrhotic SOF RBV +/- PEG NS3 SIM +SOF + RBV 24 wks LDV/SOF + RBV 12 wks EBV/GRZ (16 w if EBV RAV) + RBV 24 wks LDV/SOF 24 wks DCV + SOF +/- RBV 12 wks EBV/GRZ + RBV (16 if EBV RAV) wait Test NS5A NS3 resistance Chose best available Add ribavirin Extend to 24 wks NS5A Slide 19 of 36 wait Test NS5A NS3 resistance Chose best available Add ribavirin Extend to 24 wks AASLD/IDSA. HCV guidance. September Recommended Regimens for HCV Genotype 2 Tx Experienced Recommended non cirrhotic Recommended Cirrhotic naive wks DCV + SOF PEG RBV SOF + RBV 24 wks DCV + SOF wks DCV + SOF 24 wks DCV + SOF Slide 20 of 36 AASLD/IDSA. HCV guidance. September Recommended Regimens for HCV Genotype 3 Tx Experienced Recommended non cirrhotic Recommended Cirrhotic naive 24 wks DCV + SOF +/- RBV PEG RBV SOF + RBV 24 wks DCV + SOF +RBV + RBV 24 wks DCV + SOF + RBV 24 wks DCV + SOF +RBV Slide 21 of 36 AASLD/IDSA. HCV guidance. September New York, New York: February 24,
7 Slide 22 of 36 DAA and ART: where to find guidance Managing ART /DAA drug interactions can be complex Good data available and many excellent resources AASLD/IDSA Guidelines: University of Liverpool HCV Drug interactions: Slide 23 of 36 SOF Ledipasvir VEL Daclatasvir P/r/O + D EBR/GZP ATV/r No data LDV ; ATV a VEL ; ATV a DCV * ATV ; PAR GZP & EBV, ATV DRV/r SOF ; DRV LDV ; DRV a VEL ; DRV a DCV, DRV DRV ; PAR / GZP & ELB ; DRV LPV/r No data No data VEL ; LPV a DCV, LPV LPV ; PAR GZP & EBR ; DRV EFV SOF ; EFV LDV EFV VEL ; EFV DCV ** No PK data** GZP & EBR, EFV RPV SOF ; RPV LDV ; RPV VEL ; RPV No PK data (clinical trial data ok) PAR ; RPV GZP & EBR ; RPV ETV No data No data No Data DCV ** No data No data RAL SOF ; RAL LDV ; RAL VEL ; RAL No PK data (clinical trial data ok) ELV/co b PrOD ; RAL GZP & EBR ; RAL Cobi ; SOF a LDV ; SOF a VEL ; COBI No data No data GZP & EBV, ATV DTG No data LDV ; DOL VEL ; RAL DCV ; TFV PAR ; DOL GZP & EBR ; DOL MVC No data No data No Data No data No data No data TDF SOF ;TFV LDV ; TFV VEL ; TFV DCV ; TFV PrOD ; TFV GZP & EBR ; TFV TAF SOF ;TFV LDV ;TFV VEL ;TFV No Data No Data No Data *Decrease DCV dose to 30mg QD, **Increase DCV dose to 90mg QD, *** 3D + EFV led to premature study discontinuation due to toxicities, a issue when using TDF Adapted from Jennifer Kiser Slide 24 of 36 SOF Ledipasvir VEL Daclatasvir P/r/O + D EBR/GZP ATV/r No data LDV ; ATV a VEL ; ATV a DCV * ATV ; PAR GZP & EBV, ATV DRV/r SOF ; DRV LDV ; DRV a VEL ; DRV a DCV, DRV DRV ; PAR / GZP & ELB ; DRV LPV/r No data No data VEL ; LPV a DCV, LPV LPV ; PAR GZP & EBR ; DRV EFV SOF ; EFV LDV EFV VEL ; EFV DCV ** No PK data** GZP & EBR, EFV RPV SOF ; RPV LDV ; RPV VEL ; RPV No PK data (clinical trial data ok) PAR ; RPV GZP & EBR ; RPV ETV No data No data No Data DCV ** No data No data RAL SOF ; RAL LDV ; RAL VEL ; RAL No PK data (clinical trial data ok) ELV/co b PrOD ; RAL GZP & EBR ; RAL Cobi ; SOF a LDV ; SOF a VEL ; COBI No data No data GZP & EBV, ATV DTG No data LDV ; DOL VEL ; RAL DCV ; TFV PAR ; DOL GZP & EBR ; DOL MVC No data No data No Data No data No data No data TDF SOF ;TFV LDV ; TFV VEL ; TFV DCV ; TFV PrOD ; TFV GZP & EBR ; TFV TAF SOF ;TFV LDV ;TFV VEL ;TFV No Data No Data No Data Adapted from Jennifer Kiser: HCV guidelines.org/ report New York, New York: February 24,
8 SVR12 (%) Good news Challenges Genotype 3 Renal Failure/ ESRD NS5a failures with NS5a RASs Decompensated cirrhosis Slide 25 of 36 SOF/VEL cure rates 90-95%, better than SOF/RBV (Astral-3) Grazoprevir/Elbasvir an option (no ritonavir, no RBV, potentially even in GT1a) (C- SURFER) High cure rates with current DAAs + RBV Some triple therapies will be RBV-sparing SVR 95% with SOF/VEL/RBV (Astral-4) Real world : CPT A up to 94% SVR vs CPT B-C 78% (Fernando- Carillo 2016) Worse outcome in cirrhotics & treatment experiences, especially if NS5a RAVs at baseline Consider timing of treatment if transplant candidate Current options require RBV Expense and access to medications for retreatment Best outcomes with RBV Better outcome with less advanced disease Medically complex: treat with liver expert, discuss transplantation n/n = Slide 26 of IFN-Free DAA Therapy: OST vs Non-OST PTV/RTV/OMB + DSV + RBV [1,2] References in slidenotes No OST OST + DSV PTV/RTV/OMB + RBV [3] SOF/LDV + RBV [4] SOF/VEL [5] GZR/ELB [6,7] 1. Feld JJ. N Engl J Med Puoti M AASLD A Lalezari J J Hepatol Grebely J Clin Infect Dis Grebely J. Clin Infect Dis Zeuzem S Ann Intern Med Dore GJ Ann Intern Med Slide credit: clinicaloptions Recommendations Related to HCV Medication Interactions with HIV Antiretroviral Medications Rating: Class I, Level A ART switches, when needed, should be done in collaboration with the HIV practitioner. Rating: Class IIa, Level B DAC requires decrease with ritonavir-boosted atazanavir (30 mg/d) and increase with efavirenz or etravirine (90 mg/d) Elbasvir/grazoprevir FDC: should be used with ART without clinically significant interactions: abacavir, emtricitabine, enfuvirtide, lamivudine, raltegravir, dolutegravir, rilpivirine, and tenofovir. Simeprevir should be used without clinically significant interactions: abacavir, emtricitabine, enfuvirtide, lamivudine, maraviroc, raltegravir, (and probably dolutegravir), rilpivirine, and tenofovir. Sofosbuvir/velpatasvir cannot be used with efavirenz (increases TDF- check CrCl) or etravirine. Slide 27 of 36 New York, New York: February 24,
9 Recommendations Related to HCV Medication Interactions with HIV Antiretroviral Medications Rating: Class IIa, Level C Ledipasvir (90 mg)/sofosbuvir (400 mg) FDC: most antiretrovirals. Check Cr Cl with TDF as ledipasvir increases tenofovir levels. Avoid LDV with TDF in ritonavir-boosted or cobicistat-boosted regimens, or use TAF PrOD: should be used with antiretroviral drugs with which they do not have substantial interactions: atazanavir, dolutegravir, emtricitabine, enfuvirtide, lamivudine, raltegravir, and tenofovir. Dose of ritonavir used for boosting of HIV protease inhibitors may need to be adjusted (or held) when administered with paritaprevir/ritonavir/ombitasvir plus dasabuvir and then restored when HCV treatment is completed. The HIV protease inhibitor should be administered at the same time as the fixed-dose HCV combination. Slide 28 of 36 Regimens Not Recommended for Patients with HIV/HCV Coinfection Antiretroviral treatment interruption to allow HCV therapy is Not Recommended. Rating: Class III, Level A Elbasvir/grazoprevir should NOT be used with cobicistat, efavirenz, etravirine, nevirapine, or any HIV protease inhibitor. Rating: Class III, Level B Sofosbuvir/velpatasvir should NOT be used with efavirenz, etravirine, or nevirapine. Rating: Class III, Level B Sofosbuvir-based regimens should NOT be used with tipranavir. Rating: Class III, Level B PRoD should NOT be used with darunavir, efavirenz, ritonavir-boosted lopinavir, ritonavir-boosted tipranavir, etravirine, nevirapine, cobicistat, or rilpivirine. Rating: Class III, Level B PRO with or without dasabuvir should NOT be used in HIV/HCV-coinfected individuals who are not taking antiretroviral therapy. Rating: Class III, Level B Ribavirin should NOT be used with didanosine, stavudine, or zidovudine. Rating: Class III, Level B Simeprevir should NOT be used with cobicistat, efavirenz, etravirine, nevirapine, or any HIV protease inhibitor. Rating: Class III, Level B Slide 29 of 36 Slide 30 of 36 HBV Reactivation Risk in HBV/HCV Coinfected Pts on DAAs Case reports of HBV reactivation in pts treated with SMV + SOF + ASV, [3,4] and LDV/SOF [5] Observational study of Chinese pts treated with DAAs (N = 327 screened) [6] 3/10 HBsAg+ pts experienced hepatitis due to HBV reactivation Of 124 HBsAg-/HBcAb+ pts, none experienced hepatitis due to HBV reactivation Analysis of open-label phase IIIb trial [7] RBV, [1,2] DCV No evidence of HBV reactivation in HBsAg-/HBcAb+ pts receiving LDV/SOF (n = 103) Led FDA to require boxed warning for certain DAAs regarding the risk of HBV reactivation and need for HBV screening/monitoring [8] 1. Collins JM, et al. Clin Infect Dis. 2015;61: ; 2. Ende AR, et al. J Med Case Rep. 2015;9:164; 3. Hayashi K, et al. Clin J Gastroenterol. 2016;9: ; 4. Takayama H, et al. Hepatol Res. 2016;46: ; 5. De Monte A, et al. J Clin Virol. 2016;78:27-30; 6. Wang C, et al. Clin Gastroenterol Hepatol. 2016;[Epub ahead of print]; 7. Sulkowski MS, et al. Clin Infect Dis. 2016;[Epub ahead of print]; 8. FDA. Drug Safety Communication New York, New York: February 24,
10 Slide 31 of 36 HBV Reactivation during DAA Rx for HCV Cases were not receiving HBV antiviral treatment In 8 cases, when transaminases started to rise, DAA hepatotoxicity was initial diagnosis - DAA discontinued. As patients deteriorated or failed to improve, HBV reactivation was considered among the likely diagnosis 12 cases eventually received HBV antiviral treatment Treatment for HBV was delayed in at least five of the 12 cases, and one patient died. With HBV treatment, most patients had improvement in HBV DNA, and other signs and symptoms FDA.gov HBV reactivation on DAA therapy 29 cases of HBV reactivation on HCV therapy Including HBsAg (-), HBV DNA (-) patients Mechanism-? Viral interference HCV can have known suppressive effect on HBV in dually infected patients Check HBV serologies before HCV treatment (HBsAb, sag, core Ab) Very unlikely in HIV+ patients on HBV active ART (3TC/FTC +/- Tenofovir ) Slide 32 of 36 CJ Chu Journal of Gastroenterology and Hepatology 23 (2008) Slide 33 of 36 DAAs and HCC in HCV SVR patients Reig 103 prior treated HCC received DAAs 53 complete HCC response 3 died, 16 recurrence within 5.7 months post SVR ANRS 3 cohorts receiving prior HCC treatment No difference in HCC whether received DAA or IFN Conti 344 DAA, 59 prior HCC Recurrence 17/59 (28.8%) 9/285 (3.2%) within 24 w post SVR AURIC (Austrian) 182 SVR (8 prior HCC) 16 developed HCC within 1-13 months post SVR 8.1% overall, 7.7% de novo Kobayashi 77 DAA; 528 IFN; no difference at 3 and 5 years FIB-4>3.25 5y HCC 9.66% in DAA rx, 8.37% in IFN rx(ns) Recurrence 8-30% Incidence % Within 1y post SVR J HEP 2016 Reig; ANRS; Kozbial; Conti. Kobayashi J Med Virol 2016 New York, New York: February 24,
11 Slide 34 of 36 HCC surveillance post SVR in cirrhotics? HCV cure reduces the risk of HCC Transient elastography may not be accurate post SVR in diagnosing cirrhosis If you want to stop screening you need to do liver biopsy Increased risk of HCC in non HIV with Chronic and heavy alcohol intake, Metabolic syndrome and diabetes mellitus Unclear if need to screen All F3 Older age Less HIV control Continued surveillance with q 6 month imaging and AFP Conclusions HCV treatment options for HIV/HCV patients are excellent DDIs with DAAs prove the most problematic However excellent tools are available online After HCV cure: continue HCC surveillance and assess for reinfection Stay vigilant in this rapidly changing field: HBV reactivation can occur with DAA therapy It is easier to treat and there are greater needs for us all to treat We have the tools and the vision to work towards global elimination by 2030 Slide 35 of 36 HCV Treatment is essential but not sufficient US HCV care cascade, pre-daa era, DIAGNOSIS ACCESS to HCV CARE ACCESS to HCV MEDICATIONS PREVENTION OF REINFECTION Slide 36 of 36 New York, New York: February 24,
Disclosures. Hepatitis C: the 2016 Perspective. The Take Home. Glossary 12/9/16
Disclosures Hepatitis C: the 2016 Perspective Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF I have received research grant support to UCSF related to HCV from the following:
More informationHepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF
Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More information3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationTreatment of HCV in HIV/HCV Coinfection
Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Clinical Infectious Diseases IDSA FEATURES Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel a (See
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C ew Medications, New Hope and New. V. Opportunities for Primary Care. Outline. HCV Disease Outcomes in the US 9/21/2016
Hepatitis C ew Medications, New Hope and New Opportunities for Primary Care Primary Care Principles and Practice October 14, 2016 Disclosures: Grant support Gilead Sciences, Inc Quality improvement Systematized
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationCurrent Management of Hepatitis C Virus Infection
Current Management of Hepatitis C Virus Infection Kristen M. Marks, MD Assistant Professor Weill Cornell Medicine New York, New York FORMATTED: 10/13/16 Financial Relationships With Commercial Entities
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationOutline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures
5/24/16 Hepatitis C: The New Landscape Advances in Internal Medicine May 24, 2016 I have no disclosures Rena K. Fo, MD Professor of Clinical Medicine, UCSF Outline I. Current HCV outcomes in the US II.
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationP4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines
P4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines Presenter: Stacey B. Trooskin, M.D., Ph.D Director of Viral Hepatitis Programs Philadelphia FIGHT Community Health Centers
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationSEVERE LIVER DISEASES & HIV INFECTION
SEVERE LIVER DISEASES & HIV INFECTION SEVERE LIVER DISEASES AND HIV INFECTION Liver diseases ranks as a serious cause of morbidity and mortality in HIV infected persons, whose HIV disease is effectively
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationInitial Treatment of the Hepatitis C Virus-Infected Patient
IDSA/AASLD www.hcvguidelines.org http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-ontreatment-of-hepatitis-c-216 Initial Treatment of the Hepatitis
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationSlide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationReal World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs
Real World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Financial Relationships
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationDisclosures. Lisa M. Chirch, MD, FIDSA has disclosed that she has served on advisory boards for Gilead Sciences and Melinta Therapeutics.
HEPATITIS C IN 2017 Lisa M. Chirch, M.D. Associate Professor of Medicine University of Connecticut Health Center A Local Performance Site of the New England AETC Disclosures Lisa M. Chirch, MD, FIDSA has
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More information5/2/2016. Kara W. Chew, MD, MS Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California
Advances in Hepatitis C Virus Treatment for HIV-Infected Persons: Have We Reached the End of the Rainbow? Kara W. Chew, MD, MS Assistant Clinical Professor of Medicine David Geffen School of Medicine at
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationViral hepatitis in patients living with HIV: can we still speak of special population?
Viral hepatitis in patients living with HIV: can we still speak of special population? Maurizio Bonacini, M.D., A.G.A.F. Mission Gastroenterology and Hepatology San Francisco, CA YES for HBV Excluded by
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JUNE 8, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationBeginner HCV Management
Disclosures Beginner HCV Management None Rachel Rutishauser, MD, PhD University of California, San Francisco Zuckerberg San Francisco General Hospital and Trauma Center When to treat? Treatment is recommended
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS
Hepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS April 15, 2016 Ashwin Balagopal, M.D. and Michael Chattergoon, M.D./Ph.D. Division of Infectious Diseases Center for Viral Hepatitis Research
More informationUpdates on the AASLD/IDSA HCV Guidance
Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More information